NCT03585803View on ClinicalTrials.gov

A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 11, 2018

Primary Completion Date

September 11, 2019

Study Completion Date

November 28, 2019

Conditions
Acute Radiation Syndrome
Interventions
DRUG

KMRC011 5μg or Placebo

Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml

DRUG

KMRC011 10μg or Placebo

Intramuscular Injection of KMRC011 10μg or Placebo(Normal Saline) 0.2ml

DRUG

KMRC011 15μg or Placebo

Intramuscular Injection of KMRC011 15μg or Placebo(Normal Saline) 0.3ml

DRUG

KMRC011 20μg or Placebo

Intramuscular Injection of KMRC011 30μg or Placebo(Normal Saline) 0.4ml

DRUG

KMRC011 25μg or Placebo

Intramuscular Injection of KMRC011 45μg or Placebo(Normal Saline) 0.5ml

Trial Locations (1)

06351

Samsung Medical Center, Gangnam-gu

Sponsors
All Listed Sponsors
lead

Intron Biotechnology, Inc.

INDUSTRY